Proton Pump Inhibitors and Dual Antiplatelet Therapy for ACS 883 3.2.3.1.6. Glycoprotein IIb/IIIa Receptor Antagonists 884 3.3. Initial Invasive Versus Initial Conservative Strategies: Recommendations 885 3.3.3.1. Timing of Invasive Therapy 885 5. Late Hospital Care, Hospital Discharge, and Posthospital Discharge Care 890 5.2. Long-Term Medical Therapy and Secondary Prevention 890 5.2.1. Convalescent and Long-Term Antiplatelet Therapy: Recommendations 890 5.2.6. Warfarin Therapy: Recommendations 892 6. Special Groups 892 6.2. Diabetes Mellitus: Recommendations 892 6.2.1.1. Intensive Glucose Control 892 6.5. Chronic Kidney Disease: Recommendations 893 6.5.1. Angiography in Patients With CKD 893 7. Conclusions and Future Directions 895 7.1. Quality of Care and Outcomes for UA/NSTEMI: Recommendation 895 7.1.1. Quality Care and Outcomes 895 Appendix 1. Author Relationships With Industry and Other Entities (Relevant) 901 Appendix 2. Reviewer Relationships With Industry and Other Entities (Relevant) 903 Appendix 3. Dosing Table for Antiplatelet and Anticoagulant Therapy Discussed in This Focused Update to Support PCI in UA/NSTEMI 906 Appendix 4. Comparisons Among Orally Effective P2Y12 Inhibitors 908 Appendix 5. Flowchart for Class I and Class IIa Recommendations for Initial Management of UA/NSTEMI 909 Appendix 6. Selection of Initial Treatment Strategy: Invasive Versus Conservative Strategy 910 Preamble Keeping pace with the stream of new data and evolving evidence on which guideline recommendations are based is an ongoing challenge to timely development of clinical practice guidelines. In an effort to respond promptly to new evidence, the American College of Cardiology Foundation (ACCF)/American Heart Association (AHA) Task Force on Practice Guidelines (Task Force) has created a focused update process to revise the existing guideline recommendations that are affected by the evolving data or opinion. New evidence is reviewed in an ongoing fashion to more efficiently respond to important science and treatment trends that could have a major impact on patient outcomes and quality of care. 